Tuesday, July, 16, 2019 05:00:52

Fulcrum bags global rights for GSK’s failed trial drug Losmapimod

Fulcrum plans to initiate a Phase 2b clinical trial in mid-2019 on patients with FSHD in the U.S. and Europe. Fulcrum Therapeutics, a biotechnology firm focused on discovering and developing therapies to rebalance gene expression, has recently announced its exclusive global license agreement with British …

Lilly & Avidity ink new licensing & research collaboration agreement

The collaboration specifically focuses on the development, discovery and commercialization for potential new drugs. Under the terms of the agreement, Avidity would receive $20 million in upfront payment and a $15 million investment. Eli Lilly and Company (Lilly), a renowned American pharmaceutical company, has reportedly …

Alembic Pharma receives FDA approval for Teriflunomide tablets

The company now possesses over 91 ANDA approvals, approximately 79 final approvals & 12 tentative approvals, from the FDA. Company shares went up by 1% following the FDA approval of the Teriflunomide tablets. Alembic Pharmaceuticals Ltd (Alembic), a renowned Indian multinational pharmaceutical company, has reportedly …

Roche Pharma introduces Hemophilia A treatment drug in India

The new drug would be sold under the brand name Hemlibra in the country It represents an entirely new way to manage Hemophilia A and reviews the standard of care Roche Pharmaceuticals, the Swiss multinational healthcare company, has reportedly announced that it has introduced Emicizumab …

Dr. Reddy’s Laboratories acquires 42 ANDAs portfolio in the U.S.

The portfolio in question includes over 30 generic injectable products.  The latest acquisition expands Dr. Reddy’s current portfolio by a considerable margin. Dr. Reddy’s Laboratories Ltd., (Dr. Reddy’s), a renowned Indian multinational pharmaceutical firm based out of Hyderabad, has reportedly entered into a definitive agreement …

Catalent Inc to acquire Paragon Bioservices in a $1.2 billion deal

The acquisition would be helping Catalent in expanding its capabilities of developing costly & specialized gene therapy treatments. The company would be carrying out the acquisition through an all-cash deal, scheduled to be announced soon. Catalent, Inc., (Catalent), a New Jersey-based technology & pharmaceutical firm, …

Cerner and naviHealth to add a new offering to BPCI Advanced program

Cerner and naviHealth have reportedly expanded their relationship in a bid to introduce new offerings for bundled payments for care improvement advanced (BPCI Advanced) program, projected to support inexpensive and accessible healthcare centered on the patient. As per BPCI Advanced, benefactors prospectively approve a pre-defined …